Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -13.40% is 60% above its 5-year average of -33.56%, near the high end of its 5-year range (-68.99%–-2.61%).
As of the fiscal period ended Tuesday, June 30, 2026. 31.93% above its 12-month average of -19.69%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -13.40%.
RETURN ON EQUITY (ROE)
-13.40%
RETURN ON EQUITY (ROE) AVG TTM
-19.69%
RETURN ON EQUITY (ROE) AVG 3Y
-40.88%
RETURN ON EQUITY (ROE) AVG 5Y
-33.56%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+31.93%
CURRENT VS 3Y AVG
+67.21%
CURRENT VS 5Y AVG
+60.06%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
+68.09%
vs the sector median at left
Tarsus Pharmaceuticals, Inc.
Market Cap
$3.19B
Return on Equity (ROE)
-13.40%
TTM Avg
-19.69%
3Y Avg
-40.88%
5Y Avg
-33.56%
Market Cap
$3.12B
Return on Equity (ROE)
-63.59%
TTM Avg
-115.27%
3Y Avg
-69.35%
5Y Avg
-25.98%
Market Cap
$3.30B
Return on Equity (ROE)
26.08%
TTM Avg
3.42%
3Y Avg
-20.94%
5Y Avg
-16.18%
Market Cap
$3.31B
Return on Equity (ROE)
-130.98%
TTM Avg
-34.38%
3Y Avg
-35.20%
5Y Avg
-30.70%
Market Cap
$3.06B
Return on Equity (ROE)
-61.24%
TTM Avg
-42.47%
3Y Avg
-32.58%
5Y Avg
-25.72%
Market Cap
$3.03B
Return on Equity (ROE)
-11.83%
TTM Avg
-25.64%
3Y Avg
-7.84%
5Y Avg
-12.83%
Market Cap
$3.36B
Return on Equity (ROE)
N/A
TTM Avg
336.99%
3Y Avg
336.99%
5Y Avg
336.99%
Market Cap
$3.38B
Return on Equity (ROE)
29.12%
TTM Avg
31.38%
3Y Avg
-1.34%
5Y Avg
-13.55%
Market Cap
$2.99B
Return on Equity (ROE)
12.93%
TTM Avg
-48.70%
3Y Avg
-135.42%
5Y Avg
-110.19%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | $3.19B | -13.40% | -19.69% | -40.88% | -33.56% |
| Amylyx Pharmaceuticals, Inc. (AMLX)vs › | $3.12B | -63.59% | -115.27% | -69.35% | -25.98% |
| CareDx, Inc (CDNA)vs › | $3.30B | 26.08% | 3.42% | -20.94% | -16.18% |
| Viking Therapeutics, Inc. (VKTX)vs › | $3.31B | -130.98% | -34.38% | -35.20% | -30.70% |
| Denali Therapeutics Inc. (DNLI)vs › | $3.06B | -61.24% | -42.47% | -32.58% | -25.72% |
| Enliven Therapeutics, Inc. (ELVN)vs › | $3.03B | -11.83% | -25.64% | -7.84% | -12.83% |
| Parabilis Medicines, Inc. (PBLS)vs › | $3.36B | N/A | 336.99% | 336.99% | 336.99% |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.38B | 29.12% | 31.38% | -1.34% | -13.55% |
| Arcutis Biotherapeutics, Inc. (ARQT)vs › | $2.99B | 12.93% | -48.70% | -135.42% | -110.19% |
| Pulse Biosciences, Inc. (PLSE)vs › | $3.44B | -80.46% | -68.44% | 592.63% | 329.15% |
ROE
-13.4%
ROA
-7.6%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -13.40% |
| 2026-03-31 | -13.83% |
| 2025-12-31 | -19.34% |
| 2025-09-30 | -24.22% |
| 2025-06-30 | -27.66% |
| 2025-03-31 | -30.64% |
| 2024-12-31 | -51.46% |
| 2024-09-30 | -56.57% |
| 2024-06-30 | -59.49% |
| 2024-03-31 | -53.85% |
| 2023-12-31 | -68.99% |
| 2023-09-30 | -50.35% |
| 2023-06-30 | -61.57% |
| 2023-03-31 | -37.64% |
| 2022-12-31 | -32.19% |
| 2022-09-30 | -31.26% |
| 2022-06-30 | -25.52% |
| 2022-03-31 | -29.82% |
| 2021-12-31 | -8.37% |
| 2021-09-30 | -5.91% |
| 2021-06-30 | -2.61% |
| 2021-03-31 | -7.95% |
| 2020-12-31 | -16.15% |
| 2020-06-30 | -13.94% |
